{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:49Z","timestamp":1791896209351,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2019B090904008"],"award-info":[{"award-number":["2019B090904008"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377097"],"award-info":[{"award-number":["22377097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejmech.2025.117378","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:06:04Z","timestamp":1739181964000},"page":"117378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12\/13"],"prefix":"10.1016","volume":"288","author":[{"given":"Meng","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziteng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanrui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-3784","authenticated-orcid":false,"given":"Mingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117378_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ncb1109-1275","article-title":"Cyclin-dependent kinases: a family portrait","volume":"11","author":"Malumbres","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117378_bib2","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117378_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ceb.2013.08.004","article-title":"Targeting cyclin-dependent kinases in anti-neoplastic therapy","volume":"25","author":"Bruy\u00e8re","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117378_bib4","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1128\/MCB.06267-11","article-title":"Interaction of cyclin-dependent kinase 12\/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II","volume":"32","author":"Cheng","year":"2023","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117378_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s12276-020-0442-9","article-title":"Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation","volume":"52","author":"Choi","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117378_bib6","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117378_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.CAN-20-2245","article-title":"Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117378_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cells9061483","article-title":"CDK12: a potent target and biomarker for human cancer therapy","volume":"9","author":"Liang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117378_bib9","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1634\/theoncologist.2019-0214","article-title":"Pan-cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype","volume":"24","author":"Sokol","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.117378_bib10","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.7150\/thno.46137","article-title":"CDK12 and PAK2 as novel therapeutic targets for human gastric cancer","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117378_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","article-title":"EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in ewing sarcoma","volume":"33","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117378_bib12","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.drudis.2020.09.035","article-title":"CDK12: a potential therapeutic target in cancer","volume":"25","author":"Emadi","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117378_bib13","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/acs.biochem.1c00353","article-title":"Novel mechanisms of molecular glue-induced protein degradation","volume":"60","author":"Alabi","year":"2021","journal-title":"Biochem."},{"key":"10.1016\/j.ejmech.2025.117378_bib14","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1039\/D3MD00004D","article-title":"Research progress of anticancer drugs targeting CDK12","volume":"14","author":"Yan","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117378_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117378_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59994","article-title":"Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation","volume":"9","author":"Lv","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2025.117378_bib18","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/onc.2008.191","article-title":"CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases","volume":"27","author":"Bettayeb","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117378_bib19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117378_bib20","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.1c02184","article-title":"3,5,7-Substituted pyrazolo[4,3-d]Pyrimidine inhibitors of cyclin-dependent kinases and cyclin K degraders","volume":"65","author":"Jorda","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116014","article-title":"Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo","volume":"264","author":"Kuchukulla","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114603","article-title":"Current progress and novel strategies that target CDK12 for drug discovery","volume":"240","author":"Lei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117378_bib24","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1021\/acs.jmedchem.8b00683","article-title":"Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) inhibitors","volume":"61","author":"Ito","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cmdc.201700695","article-title":"Structure\u2010based design of selective noncovalent CDK12 inhibitors","volume":"13","author":"Johannes","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117378_bib26","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1002\/mog2.56","article-title":"Development of covalent inhibitors: principle, design, and application in cancer","volume":"2","author":"Zheng","year":"2023","journal-title":"MedComm - Oncol"},{"key":"10.1016\/j.ejmech.2025.117378_bib27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117378_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113481","article-title":"Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in Ewing sarcoma","volume":"221","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib29","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1021\/acs.jmedchem.9b01929","article-title":"Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12\/13","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117378_bib30","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1038\/s41467-024-50642-0","article-title":"Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117378_bib31","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.bmcl.2018.10.020","article-title":"Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy","volume":"28","author":"Rana","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:45:44Z","timestamp":1740768344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"alternative-id":["S0223523425001436"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117378","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12\/13","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117378"}}